首页> 美国卫生研究院文献>ACS AuthorChoice >Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model
【2h】

Biodistribution and Pharmacokinetic Analysis of Paclitaxel and Ceramide Administered in Multifunctional Polymer-Blend Nanoparticles in Drug Resistant Breast Cancer Model

机译:紫杉醇和神经酰胺在耐药性乳腺癌模型中的多功能聚合物混合纳米颗粒中的生物分布和药代动力学分析。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we have investigated the biodistribution and pharmacokinetic analysis of paclitaxel (PTX) and the apoptotic signaling molecule, C6-ceramide (CER), when administered in a multifunctional polymer-blend nanoparticle formulation to female nude mice bearing an orthotopic drug sensitive MCF7 and multidrug resistant MCF7TR (MDR-1 positive) human breast adenocarcinoma. A polymer-blend nanoparticle system was engineered to incorporate temporally controlled sequential release of the combination drug payload. Hereby, PTX was encapsulated in the pH-responsive rapid releasing polymer, poly(beta-amino ester) (PbAE), while CER was present in the slow releasing polymer, poly(d,l-lactide-co-glycolide) (PLGA) within these blend nanoparticles. When particle formulations were administered intravenously to MCF7 and MCF7TR tumor bearing mice, higher concentrations of PTX were found in the blood due to longer retention time and an enhanced tumor accumulation relative to administration of free drug. In addition, the PLGA/PbAE blend nanoparticles were effective in enhancing the residence time of both drugs at the tumor site by reducing systemic clearance. Overall, these results are highly encouraging for development of multifunctional polymer-blend nanoparticle formulations that can be used for temporal-controlled administration of two drugs from a single formulation.
机译:在这项研究中,我们研究了紫杉醇(PTX)和凋亡信号分子C6-神经酰胺(CER)的生物分布和药代动力学分析,将其以多功能聚合物共混纳米颗粒制剂给药于荷有原位药物敏感性MCF7的雌性裸鼠和多药耐药的MCF7TR(MDR-1阳性)人乳腺癌。设计了一种聚合物共混纳米颗粒系统,以结合组合药物有效载荷的时间控制顺序释放。因此,PTX被封装在pH响应快速释放聚合物聚(β-氨基酯)(PbAE)中,而CER存在于缓慢释放聚合物聚(d,1-丙交酯-乙交酯)(PLGA)中在这些混合纳米粒子中。当将颗粒制剂静脉内给药于带有MCF7和MCF7TR荷瘤小鼠的小鼠时,由于更长的保留时间和相对于游离药物给药而增加的肿瘤积累,在血液中发现了更高浓度的PTX。此外,PLGA / PbAE共混物纳米颗粒通过降低系统清除率,有效延长了两种药物在肿瘤部位的停留时间。总体而言,这些结果对于多功能聚合物共混纳米颗粒制剂的开发非常令人鼓舞,该制剂可用于从单一制剂中两种药物的时间控制给药。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号